Humanwell Healthcare (Group) Co.,Ltd. (SHA: 600079)

Market Cap	38.17B
Revenue (ttm)	25.56B
Net Income (ttm)	1.96B
Shares Out	1.61B
EPS (ttm)	1.19
PE Ratio	19.92
Forward PE	16.38
Dividend	0.30 (1.25%)
Ex-Dividend Date	Oct 11, 2024

Volume	12,324,900
Open	23.91
Previous Close	24.03
Day's Range	23.42 - 24.08
52-Week Range	15.68 - 25.90
Beta	0.84
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About Humanwell Healthcare (Group) Co.,Ltd.

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia using artificial respiration; remifentanil hydrochloride for Injection for induction and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injectio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 17,676
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600079

Financial Performance

In 2023, Humanwell Healthcare (Group) Co.,Ltd.'s revenue was 24.52 billion, an increase of 9.79% compared to the previous year's 22.34 billion. Earnings were 2.13 billion, a decrease of -14.07%.